Cargando…

miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD)

MicroRNA contribute to tumor radiation resistance, which is an important clinical problem, and thus we are interested in identifying and characterizing their function. We demonstrate that miR-620 contributes to radiation resistance in cancer cells by increasing proliferation, and decreasing the G2/M...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiaoyong, Taeb, Samira, Jahangiri, Sahar, Korpela, Elina, Cadonic, Ivan, Yu, Nancy, Krylov, Sergey N., Fokas, Emmanouil, Boutros, Paul C., Liu, Stanley K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673174/
https://www.ncbi.nlm.nih.gov/pubmed/26068950
_version_ 1782404683115003904
author Huang, Xiaoyong
Taeb, Samira
Jahangiri, Sahar
Korpela, Elina
Cadonic, Ivan
Yu, Nancy
Krylov, Sergey N.
Fokas, Emmanouil
Boutros, Paul C.
Liu, Stanley K.
author_facet Huang, Xiaoyong
Taeb, Samira
Jahangiri, Sahar
Korpela, Elina
Cadonic, Ivan
Yu, Nancy
Krylov, Sergey N.
Fokas, Emmanouil
Boutros, Paul C.
Liu, Stanley K.
author_sort Huang, Xiaoyong
collection PubMed
description MicroRNA contribute to tumor radiation resistance, which is an important clinical problem, and thus we are interested in identifying and characterizing their function. We demonstrate that miR-620 contributes to radiation resistance in cancer cells by increasing proliferation, and decreasing the G2/M block. We identify the hydroxyprostaglandin dehydrogenase 15-(nicotinamide adenine dinucleotide) (HPGD/15-PGDH) tumor suppressor gene as a direct miR-620 target, which results in increased prostaglandin E2 (PGE2) levels. Furthermore, we show that siRNA targeting of HPGD or administration of exogenous PGE2 recapitulates radioresistance. Targeting of the EP2 receptor that responds to PGE2 using pharmacological or genetic approaches, abrogates radioresistance. Tumor xenograft experiments confirm that miR-620 increases proliferation and tumor radioresistance in vivo. Regulation of PGE2 levels via targeting of HPGD by miR-620 is an innovative manner by which a microRNA can induce radiation resistance.
format Online
Article
Text
id pubmed-4673174
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-46731742015-12-23 miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD) Huang, Xiaoyong Taeb, Samira Jahangiri, Sahar Korpela, Elina Cadonic, Ivan Yu, Nancy Krylov, Sergey N. Fokas, Emmanouil Boutros, Paul C. Liu, Stanley K. Oncotarget Research Paper MicroRNA contribute to tumor radiation resistance, which is an important clinical problem, and thus we are interested in identifying and characterizing their function. We demonstrate that miR-620 contributes to radiation resistance in cancer cells by increasing proliferation, and decreasing the G2/M block. We identify the hydroxyprostaglandin dehydrogenase 15-(nicotinamide adenine dinucleotide) (HPGD/15-PGDH) tumor suppressor gene as a direct miR-620 target, which results in increased prostaglandin E2 (PGE2) levels. Furthermore, we show that siRNA targeting of HPGD or administration of exogenous PGE2 recapitulates radioresistance. Targeting of the EP2 receptor that responds to PGE2 using pharmacological or genetic approaches, abrogates radioresistance. Tumor xenograft experiments confirm that miR-620 increases proliferation and tumor radioresistance in vivo. Regulation of PGE2 levels via targeting of HPGD by miR-620 is an innovative manner by which a microRNA can induce radiation resistance. Impact Journals LLC 2015-06-04 /pmc/articles/PMC4673174/ /pubmed/26068950 Text en Copyright: © 2015 Huang et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Huang, Xiaoyong
Taeb, Samira
Jahangiri, Sahar
Korpela, Elina
Cadonic, Ivan
Yu, Nancy
Krylov, Sergey N.
Fokas, Emmanouil
Boutros, Paul C.
Liu, Stanley K.
miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD)
title miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD)
title_full miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD)
title_fullStr miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD)
title_full_unstemmed miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD)
title_short miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD)
title_sort mir-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (hpgd)
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673174/
https://www.ncbi.nlm.nih.gov/pubmed/26068950
work_keys_str_mv AT huangxiaoyong mir620promotestumorradioresistancebytargeting15hydroxyprostaglandindehydrogenasehpgd
AT taebsamira mir620promotestumorradioresistancebytargeting15hydroxyprostaglandindehydrogenasehpgd
AT jahangirisahar mir620promotestumorradioresistancebytargeting15hydroxyprostaglandindehydrogenasehpgd
AT korpelaelina mir620promotestumorradioresistancebytargeting15hydroxyprostaglandindehydrogenasehpgd
AT cadonicivan mir620promotestumorradioresistancebytargeting15hydroxyprostaglandindehydrogenasehpgd
AT yunancy mir620promotestumorradioresistancebytargeting15hydroxyprostaglandindehydrogenasehpgd
AT krylovsergeyn mir620promotestumorradioresistancebytargeting15hydroxyprostaglandindehydrogenasehpgd
AT fokasemmanouil mir620promotestumorradioresistancebytargeting15hydroxyprostaglandindehydrogenasehpgd
AT boutrospaulc mir620promotestumorradioresistancebytargeting15hydroxyprostaglandindehydrogenasehpgd
AT liustanleyk mir620promotestumorradioresistancebytargeting15hydroxyprostaglandindehydrogenasehpgd